Search details
1.
High Prevalence of SARS-CoV-2 Omicron Infection Despite High Seroprevalence, Sweden, 2022.
Emerg Infect Dis
; 29(6): 1240-1243, 2023 06.
Article
in English
| MEDLINE | ID: mdl-37141616
2.
Psychosocial factors and hippocampal subfields: The Medea-7T study.
Hum Brain Mapp
; 44(5): 1964-1984, 2023 04 01.
Article
in English
| MEDLINE | ID: mdl-36583397
3.
Activation and Kinetics of Circulating T Follicular Helper Cells, Specific Plasmablast Response, and Development of Neutralizing Antibodies following Yellow Fever Virus Vaccination.
J Immunol
; 207(4): 1033-1043, 2021 08 15.
Article
in English
| MEDLINE | ID: mdl-34321231
4.
Infection Rate of SARS-CoV-2 in Asymptomatic Healthcare Workers, Sweden, June 2022.
Emerg Infect Dis
; 28(10): 2119-2121, 2022 10.
Article
in English
| MEDLINE | ID: mdl-35997692
5.
Magnitude and Functional Profile of the Human CD4+ T Cell Response throughout Primary Immunization with Tick-Borne Encephalitis Virus Vaccine.
J Immunol
; 204(4): 914-922, 2020 02 15.
Article
in English
| MEDLINE | ID: mdl-31924650
6.
Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients.
J Immunol
; 205(9): 2437-2446, 2020 11 01.
Article
in English
| MEDLINE | ID: mdl-32878912
7.
Mucosal and Serum Antibodies 3 Weeks after Symptomatic BA.2.86 Infection.
N Engl J Med
; 389(17): 1626-1628, 2023 Oct 26.
Article
in English
| MEDLINE | ID: mdl-37888924
8.
Terminal Effector CD8 T Cells Defined by an IKZF2+IL-7R- Transcriptional Signature Express FcγRIIIA, Expand in HIV Infection, and Mediate Potent HIV-Specific Antibody-Dependent Cellular Cytotoxicity.
J Immunol
; 203(8): 2210-2221, 2019 10 15.
Article
in English
| MEDLINE | ID: mdl-31519862
9.
Anti-Spike Mucosal IgA Protection against SARS-CoV-2 Omicron Infection.
N Engl J Med
; 387(14): 1333-1336, 2022 10 06.
Article
in English
| MEDLINE | ID: mdl-36103621
10.
NK Cell Responses to Human Tick-Borne Encephalitis Virus Infection.
J Immunol
; 197(7): 2762-71, 2016 10 01.
Article
in English
| MEDLINE | ID: mdl-27543616
11.
Specificity and dynamics of effector and memory CD8 T cell responses in human tick-borne encephalitis virus infection.
PLoS Pathog
; 11(1): e1004622, 2015 Jan.
Article
in English
| MEDLINE | ID: mdl-25611738
12.
The Human NK Cell Response to Yellow Fever Virus 17D Is Primarily Governed by NK Cell Differentiation Independently of NK Cell Education.
J Immunol
; 195(7): 3262-72, 2015 Oct 01.
Article
in English
| MEDLINE | ID: mdl-26283480
13.
A hippocampal insulin-growth factor 2 pathway regulates the extinction of fear memories.
EMBO J
; 30(19): 4071-83, 2011 Aug 26.
Article
in English
| MEDLINE | ID: mdl-21873981
14.
Temporal dynamics of the primary human T cell response to yellow fever virus 17D as it matures from an effector- to a memory-type response.
J Immunol
; 190(5): 2150-8, 2013 Mar 01.
Article
in English
| MEDLINE | ID: mdl-23338234
15.
Clonally heritable gene expression imparts a layer of diversity within cell types.
Cell Syst
; 15(2): 149-165.e10, 2024 Feb 21.
Article
in English
| MEDLINE | ID: mdl-38340731
16.
Comparison of SARS-CoV-2 spike-specific IgA and IgG in nasal secretions, saliva and serum.
Front Immunol
; 15: 1346749, 2024.
Article
in English
| MEDLINE | ID: mdl-38558811
17.
Safety and immunogenicity following co-administration of Yellow fever vaccine with Tick-borne encephalitis or Japanese encephalitis vaccines: Results from an open label, non-randomized clinical trial.
PLoS Negl Trop Dis
; 17(2): e0010616, 2023 02.
Article
in English
| MEDLINE | ID: mdl-36758067
18.
Correlates of protection and viral load trajectories in omicron breakthrough infections in triple vaccinated healthcare workers.
Nat Commun
; 14(1): 1577, 2023 03 22.
Article
in English
| MEDLINE | ID: mdl-36949041
19.
Vaccine-induced correlate of protection against fatal COVID-19 in older and frail adults during waves of neutralization-resistant variants of concern: an observational study.
Lancet Reg Health Eur
; : 100646, 2023 May 06.
Article
in English
| MEDLINE | ID: mdl-37363799
20.
Duration of SARS-CoV-2 Immune Responses Up to Six Months Following Homologous or Heterologous Primary Immunization with ChAdOx1 nCoV-19 and BNT162b2 mRNA Vaccines.
Vaccines (Basel)
; 10(3)2022 Feb 24.
Article
in English
| MEDLINE | ID: mdl-35334989